BioPharmSignal logoBioPharmSignal

Biotech News

Medpace Holdings, Inc. Reports Second Quarter 2025 Results

Medpace (MEDP)MedpaceEarnings

Revenue of $603.3 million in the second quarter of 2025 increased 14.2% from revenue of $528.1 million for the comparable prior-year period, representing a backlog conversion rate of 21.2%. Net new business awards were $620.5 million in the second quarter of 2025, representing an increase of 12.6%

Related news

MEDPMedpace2026-07-22 20:15 EST

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

MEDPMedpace2026-06-16 20:23 EST

Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026

View all latest news

Medpace

Full-Service Clinical Research Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies. Therapeutic and Scientific Expertise The company uses physician leadership and therapeutic-area specialists to support protocol...

Recent company news

MEDPMedpace2026-07-22 20:15 EST

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

MEDPMedpace2026-06-16 20:23 EST

Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026

MEDPMedpace2026-04-22 20:15 EST

Medpace Holdings, Inc. Reports First Quarter 2026 Results

MEDPMedpace2026-03-24 20:05 EST

Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

MEDPMedpace2026-02-09 21:15 EST

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

Stock data

Close
585.01 USD
Market cap
12.73B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States